All News

US health care faces massive shifts: rising ACA deductibles, federal health leadership shakeups, and major care gaps in women's health and dermatology.

A new training framework operationalizes brachytherapy competencies for soft tissue sarcoma, covering implant geometry, CT planning, dose optimization, toxicity management, and radiation safety.

New review details biologic, psychosocial, and treatment barriers shaping outcomes in AYA acute lymphoblastic leukemia (ALL).

Endometriosis is often mistaken for IBS, fibroids, UTIs, PID, and ovarian cysts, potentially delaying diagnosis, treatment, and fertility care for years.

The FDA approves Datroway for first-line metastatic triple-negative breast cancer in immunotherapy-ineligible patients.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Three hospital systems claim CVS Health secretly pocketed 340B savings meant for indigent care.

A growing body of heart failure evidence highlights the role of metabolic therapies, precision phenotyping, and next-generation mineralocorticoid receptor antagonists.

Eli Lilly's triple agonist achieved 28.3% weight loss at 80 weeks and 30.3% at 104 weeks, matching bariatric surgery levels.

The Trump administration fired USPSTF leaders, sparking concerns over the future of ACA-mandated free medical screenings and preventive care.

A prospective registry study suggests cardiac MRI scar burden and biomarkers may refine prognostic assessment beyond current sudden cardiac death models.

Chronic hand eczema care is marked by high costs, fragmented treatment, and a clinical overreliance on steroids.

From hypofractionation to proton beam therapy to pembrolizumab combinations, a new review details how 2025 reshaped the radiotherapy landscape for soft tissue sarcomas.

ACA enrollment drops 21.5% in 2026 after enhanced subsidies end. Deductibles hit record $3786 as enrollees shift to high-deductible bronze plans.

An investigational coronary IVL catheter achieved high procedural success and favorable safety outcomes in patients with severely calcified CAD.

New data examine switching biologics in severe asthma and inhaled treprostinil's effect on lung function in idiopathic pulmonary fibrosis (IPF).

TrumpRx will include more than 600 generic medications; experts say the platform’s impact on high-cost specialty drug affordability may be limited.

Poster data show the efficacy of nerandomilast in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis.

After vitiligo diagnosis, many patients remain untreated and switch quickly between therapies, according to new data on treatment patterns.

FVC percent predicted could differ in those with ILD who progress to terminal outcomes, indicating a need for patient monitoring.

Investigators found major variation in prior authorization rules across commercial insurers, highlighting limited standardization and transparency.

A new review links coexisting sleep apnea and diabetes to higher stroke risk, poorer recovery, and greater vascular damage.

Researchers found major differences between smoldering myeloma risk tools, raising concerns about overtreatment and defining “high risk.”

New findings presented at ACC.26 highlight the potential of Lp(a)-targeted therapies for patients with ASVD and elevated Lp(a).

ALIS plus MDT improved symptoms and culture conversion in newly diagnosed MACLD, according to late-breaking data presented at ATS 2026.

FDA approval brings Enhertu into early breast cancer treatment, boosting response before surgery and cutting recurrence risk after, reshaping care.

Efficacy and safety top the list for patients and physicians making R/R CLL treatment decisions, yet fewer than 1 in 3 patients felt their doctor fully answered their questions.

Early results show the potential for congestion pricing and clean air zones to be beneficial for the health of children in major cities.